(Q33392293)

26 July 2017

title

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes (English)

1 reference

26 July 2017

1 reference

1 reference

2

Hagop Kantarjian

1 reference

26 July 2017

3

Pierre Fenaux

1 reference

26 July 2017

Pamela Becker

4

1 reference

26 July 2017

Adam Boruchov

5

1 reference

26 July 2017

Agnes Guerci-Bresler

6

1 reference

26 July 2017

Kuolung Hu

7

1 reference

26 July 2017

Janet Franklin

8

1 reference

26 July 2017

Dietmar Berger

10

1 reference

26 July 2017

Mikkael A. Sekeres

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20945323

2 August 2024

Yow-Ming C. Wang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20945323

2 August 2024

language of work or name

English

0 references

publication date

13 October 2010

1 reference

full work available at URL

26 July 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.25545

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20945323

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25545

2 August 2024

1 reference

https://api.crossref.org/works/10.1002/CNCR.25545

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25545/fullpdf

2 August 2024

1 reference

https://api.crossref.org/works/10.1002/CNCR.25545

2 August 2024

1 reference

26 July 2017

volume

117

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

992-1000

1 reference

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25545

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25545

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25545

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25545

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25545

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25545

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25545

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25545

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25545

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25545

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.25545

1 reference

26 July 2017

1 reference